default author photo

Henry Bern

University College London - MRC Clinical Trials Unit

SCHOLARLY PAPERS

3

DOWNLOADS

1,810

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, University College London, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,602 (28,420)

Abstract:

Loading...

2.

A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomised, Factorial, Non-Inferiority Trial

Number of pages: 31 Posted: 01 May 2025
University College London - MRC Clinical Trials Unit, Medical Research Council Clinical Trials Unit at UCL, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Muhimbili University of Health and Allied Sciences, South African Medical Research Council, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, University College London - MRC Clinical Trials Unit, Assistance Publique-Hôpitaux de Paris - Hôpital Saint-Louis, Imperial College London, Ludwig Maximilian University of Munich (LMU) - Division of Infectious Diseases and Tropical Medicine, London School of Hygiene and Tropical Medicine - Uganda Research Unit, EuroVacc Foundation, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, IAVI, London School of Hygiene & Tropical Medicine - Uganda Research Unit, Muhimbili University of Health and Allied Sciences, Medical Research Council Clinical Trials Unit at UCL, South African Medical Research Council, University College London - MRC Clinical Trials Unit, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Mbeya Medical Research Center, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Mbeya Medical Research Center, IAVI, Imperial College London, South African Medical Research Council, International AIDS Vaccine Initiative, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Mbeya Medical Research Center, Medical Research Council Clinical Trials Unit at UCL, IAVI, South African Medical Research Council, Muhimbili University of Health and Allied Sciences, Muhimbili University of Health and Allied Sciences, Muhimbili University of Health and Allied Sciences, National Institute for Medical Research (NIMR), Eastern Virginia Medical School - CONRAD, London School of Hygiene & Tropical Medicine - Department of Global Health and Development, Imperial College London, Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Government of Uganda - Uganda Virus Research Institute (UVRI), South African Medical Research Council, South African Medical Research Council and South African Medical Research Council
Downloads 127 (572,948)

Abstract:

Loading...

HIV, Pre-exposure prophylaxis, Prevention, Risk of HIV infection, F/TAF

3.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University College London, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 81 (796,622)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response